Neurent Medical's NEUROMARK® Treatment Shows Lasting Effects in Chronic Rhinitis Patients for Two Years

NEUROMARK® Treatment for Chronic Rhinitis Shows Durable Clinical Benefits

Neurent Medical has announced impressive findings from the PARAGON clinical study, highlighting the long-term benefits of its innovative treatment, the NEUROMARK® system, for chronic rhinitis. This non-surgical solution targets chronic inflammatory sinonasal diseases and promises significant improvements for both allergic and nonallergic rhinitis patients.

Sustained Efficacy Demonstrated

The pivotal results from the study, recently published in the Ear, Nose, and Throat Journal, showcase the durability of NEUROMARK® at the two-year mark. Key findings indicate a remarkable 55% improvement in the reflective Total Nasal Symptom Score (rTNSS) from the baseline (p<0.0001). More impressively, 76% of participants reported a substantial response, defined as a reduction of 30% or more in rTNSS.

Individual symptoms, including congestion, rhinorrhea (runny nose), sneezing, and itching, showed noteworthy progress, with all four subscores reflecting significant improvement. Other associated conditions, such as postnasal drip and cough, also benefited from treatment, reinforcing NEUROMARK's broad efficacy. A significant majority of study participants—79%—achieved the minimum clinically important difference (MCID) in quality of life as assessed by the mini-Rhinoconjunctivitis Quality of Life Questionnaire (mini-RQLQ).

Continued Success After Two Years

The findings extend beyond general symptom relief, as both the Nasal Obstruction Symptom Evaluation (NOSE) score and all associated subscores remained significantly improved throughout the two-year study (p<0.0001). Why is this notable? It reflects the treatment's ability to provide patients with sustained relief from symptoms, enhancing their overall quality of life long after the initial treatment phase.

Dr. David Yen, the lead author of the study, observed that “These long-term results provide robust evidence that NEUROMARK offers durable relief for patients suffering from chronic rhinitis.” He emphasized the treatment’s potential to address not only nasal symptoms but also related issues such as cough and ear problems, marking a transformative step in managing a condition often deemed difficult to treat.

Acknowledgment of Innovative Solutions

Brian Shields, CEO of Neurent Medical, expressed enthusiasm about the study results, stating, “We are delighted to share these 2-year results, which build upon the strong 6-month findings, confirming the sustained efficacy and safety of our NEUROMARK System.” He reiterated the company's commitment to providing innovative solutions that markedly improve patients' lives while equipping ENT physicians with effective treatment tools.

Understanding the NEUROMARK® System

For clarity, the NEUROMARK System employs a minimally invasive approach through radiofrequency ablation. This technique involves creating controlled radiofrequency lesions to disrupt posterior nasal nerves—the key drivers behind chronic rhinitis symptoms. The mechanism effectively reduces inflammation by inhibiting parasympathetic nerve signaling, thus lessening symptoms such as nasal congestion.

Neurent Medical has positioned itself at the forefront of developing pioneering, non-surgical treatments tailored to address chronic inflammatory sinonasal disorders. With headquarters located in Galway, Ireland, and operations extending to Braintree, MA, this groundbreaking technology reflects a step forward in ENT practices aimed at enhancing patient care and treatment outcomes.

In conclusion, the NEUROMARK® treatment has not only demonstrated significant benefits over a two-year period but also stands as a testament to the evolving landscape of medical interventions for chronic rhinitis. Patients can look forward to enduring solutions that promise relief and an improved quality of life.